FrancophonIA/ELRC3.0 huggingface dataset:
English: In the controlled and non-controlled periods of psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis clinical studies, representing 11,581 patient-years of exposure in 6,709 patients, the median follow up was 1.0 years; 1.1 years for psoriatic disease studies, 0.6 year for Crohn's disease studies and 1.0 years for ulcerative colitis studies.
Estonian: Psoriaasi, psoriaatilise artriidi, Crohni tõve ja haavandilise koliidi kliiniliste uuringute kontrolliga ja kontrollita perioodidel, mis esindasid ekspositsiooni 11 581 patsiendiaastat 6709 patsiendil, oli järeljälgimise aja mediaan 1,0 aastat: 1,1 aastat psoriaatilise haiguse uuringutes, 0,6 aastat Crohni tõve uuringutes ja 1,0 aastat haavandilise koliidi uuringutes.
English: STELARA 45 mg solution for injection EU/1/08/494/001
Estonian: STELARA, 45 mg süstelahus EU/1/08/494/001
English: STELARA 90 mg solution for injection EU/1/08/494/002
Estonian: STELARA, 90 mg süstelahus EU/1/08/494/002
English: Table 6: Summary of Key Efficacy Measures in UNIFI-M (week 44; 52 weeks from initiation of the induction dose)
Estonian: Tabel6Kokkuvõte põhilistest efektiivsuse mõõdikutest uuringus UNIFI-M (44.nädal; 52nädalat pärast sissejuhatava ravi annuse manustamist) Platseebo* N=175
English: Renal and hepatic impairment STELARA has not been studied in these patient populations.
Estonian: Neeru- või maksakahjustusega patsientidel ei ole STELARA kasutamist uuritud.
English: PGA b of cleared or minimal N
Estonian: b puhas või minimaalne N (%)
English: Table 12: Summary of Key Efficacy Measures in UNIFI-M (week 44; 52 weeks from initiation of the induction dose)
Estonian: Tabel12Kokkuvõte põhilistest efektiivsuse mõõdikutest uuringus UNIFI-M (44.nädal; 52nädalat pärast sissejuhatava ravi annuse manustamist) Platseebo* N=175
English: Number of patients ≤ 100 kg ACR 20 response, N (%)
Estonian: ACR 20 ravivastus, N (%)
English: (kg) may start on a dose of 90 mg instead of 45 mg.
Estonian: 45 mg annuse asemel alustada ravi 90 mg annusega.
English: Alternatively, 90 mg may be used in patients with a body weight > 100 kg.
Estonian: Üle 100 kg kehakaaluga patsientidel võib teise võimalusena kasutada annust 90 mg.
English: PRE-FILLED SYRINGE LABEL TEXT (45 mg)
Estonian: TEKST SÜSTLI ETIKETIL (45 mg)
English: For the posology of the subsequent subcutaneous dosing regimen, see section 4.2 of the STELARA solution for injection (vial) and solution for injection in pre-filled syringe SmPC.
Estonian: Teave järgnevate annuste manustamisskeemi kohta: vt STELARA süstelahuse (viaalis ja süstlis) ravimi omaduste kokkuvõtte lõik 4.2.
English: Excipients: Sucrose, L-histidine, L-histidine monohydrochloride monohydrate, polysorbate 80, water for injections.
Estonian: Abiained: sahharoos, L-histidiin, L-histidiinmonovesinikkloriid-monohüdraat, polüsorbaat 80, süstevesi.
English: Histologic healing (defined as neutrophil infiltration in < 5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue) was assessed at week 8 of UNIFI-I and Week 44 of UNIFI-M. At week 8, after a single intravenous induction dose, significantly greater proportions of patients in the recommended dose group achieved histologic healing (36%) compared with patients in the placebo group (22%).
Estonian: Histoloogiline ja histoendoskoopiline limaskesta paranemine Histoloogilist paranemist (määratletud kui neutrofiilide infiltratsioon < 5% krüptidest, puuduvad krüpti destruktsioonid, erosioonid, haavandid või granulatsioonikude) hinnati UNIFI-I uuringus 8. nädalal ja UNIFI-M uuringus 44. nädalal.
English: • Bleeding, bruising, hardness, swelling and itching where the injection is given
Estonian: • Veritsus, verevalumid, kõvastumine, turse ja kihelus süstekohal
English: • A 45 mg vial is available if you need to receive less than the full 45 mg dose.
Estonian: • Kui laps peab saama vähem kui 45 mg annuse, on saadaval 45 mg viaal.
English: • Nausea
Estonian: • Väsimustunne
English: • the number of pre-filled syringes and strength is correct o If your dose is 45 mg you will get one 45 mg pre-filled syringe of Stelara o If your dose is 90 mg you will get two 45 mg pre-filled syringes of Stelara and you will need to give yourself two injections.
Estonian: o kui teie annus on 90 mg, võtate kaks 45 mg Stelara süstlit ning peate tegema endale kaks süstet.
English: STELARA 45 mg solution for injection in pre-filled syringe EU/1/08/494/003
Estonian: STELARA, 45 mg süstelahus süstlis EU/1/08/494/003
English: • the number of vials and strength is correct o If your dose is 45 mg or less, you will get one 45 mg vial of Stelara o If your dose is 90 mg you will get two 45 mg vials of Stelara and you will need to give yourself two injections.
Estonian: o kui teie annus on 45 mg või vähem, võtate ühe 45 mg Stelara viaali.
English: Improvement in HAQ-DI score from baseline was maintained through Weeks 52 and 100.
Estonian: Paranemine HAQ-DI skooris võrreldes algtasemega säilis 52. ja 100. nädalal.
English: Clinical Response (100 point), week 6 53 (21.5%) 84 (33.7%)
Estonian: Kliiniline ravivastus (100 punkti), 6. nädal Kliiniline ravivastus (100 punkti), 8. nädal Ravivastus 70 punkti, 3. nädal
English: VIAL CARTON TEXT (45 mg)
Estonian: TEKST VIAALI PAPPKARBIL (45 mg)
English: Each vial contains 130 mg ustekinumab in 26 mL of concentrate for solution for infusion.
Estonian: Üks viaal sisaldab 130 mg ustekinumabi 26 ml infusioonilahuse kontsentraadis.
English: Respiratory
Estonian: Respiratoorsed reaktsioonid
English: • Vaginal yeast infection
Estonian: • Tupe pärmseeneinfektsioon
English: Prepare the injection site
Estonian: Valmistage süstekoht ette
English: • Do not mix Stelara with other liquids for injection
Estonian: • Ärge segage Stelara't ühegi teise süstelahusega.
English: Each vial contains 45 mg of ustekinumab in 0.5 mL.
Estonian: Üks viaal sisaldab 45 mg ustekinumabi 0,5 ml lahuses.
English: Significantly greater proportions of patients were in clinical remission in both ustekinumab treated groups compared to the placebo group at week 44 (see Table 12).
Estonian: 44. nädalal oli mõlemas ustekinumabi ravirühmas saavutanud kliinilise remissiooni oluliselt suurem osa patsientidest kui platseeborühmas (vt tabel 12).
English: Solution for injection in pre-filled syringe 45 mg/0.5 mL
Estonian: Süstelahus süstlis 45 mg/0,5 ml 1 süstel
English: • Keep the pre-filled syringe in the outer carton in order to protect from light.
Estonian: • Hoida süstel välispakendis, valguse eest kaitstult.
English: Significantly higher proportions of patients maintained clinical remission and response in the ustekinumab treated groups compared to the placebo group at week 44 (see Table 4).
Estonian: 44. nädalaks oli kliinilises remissioonis ja ravivastusega patsientide osakaal ustekinumabi rühmas märkimisväärselt suurem kui platseeborühmas (vt tabel 4).
English: There was no apparent accumulation in serum ustekinumab concentration over time when given subcutaneously every 12 weeks.
Estonian: Kui ustekinumabi manustati nahaalusi iga 12 nädala järel, ei täheldatud aja jooksul mingit seerumikontsentratsiooni kumuleerumist.
English: STELARA 90 mg solution for injection in pre-filled syringe EU/1/08/494/004
Estonian: STELARA, 90 mg süstelahus süstlis EU/1/08/494/004
English: • Feeling weak
Estonian: • Pearingluse tunne
English: Each vial contains 90 mg of ustekinumab in 1 mL.
Estonian: Üks viaal sisaldab 90 mg ustekinumabi 1 ml lahuses.
English: PRE-FILLED SYRINGE LABEL TEXT (90 mg)
Estonian: TEKST SÜSTLI ETIKETIL (90 mg)
English: • the number of vials and strength is correct o If your dose is 90 mg you will get one 90 mg vial of Stelara.
Estonian: o kui teie annus on 90 mg, võtate ühe 90 mg Stelara viaali.
English: Significantly higher proportions of patients maintained clinical remission and response in the ustekinumab treated groups compared to the placebo group at week 44 (see Table 10).
Estonian: 44. nädalaks oli kliinilises remissioonis ja ravivastusega patsientide osakaal ustekinumabi rühmas märkimisväärselt suurem kui platseeborühmas (vt tabel 10).
English: After the injection:
Estonian: Pärast süstet
English: Significantly greater proportions of patients were in clinical remission in both ustekinumab treated groups compared to the placebo group at week 44 (see Table 6).
Estonian: 44. nädalal oli mõlemas ustekinumabi ravirühmas saavutanud kliinilise remissiooni oluliselt suurem osa patsientidest kui platseeborühmas (vt tabel 6).
English: Mucosal Healing
Estonian: Limaskesta paranemine
English: Talk to your doctor or pharmacist before using Stelara.
Estonian: Enne Stelara kasutamist pidage nõu oma arsti või apteekriga.
English: PASI 75 response N (%) Number of patients > 100 kg
Estonian: ≤ 100 kg patsientide arv PASI 75 ravivastuse N (%) > 100 kg patsientide arv PASI 75 ravivastuse N (%)
English: Do not touch the plunger while you do this
Estonian: Samal ajal hoiduge kolvi puudutamisest.
English: A combined endpoint of histo-endoscopic mucosal healing defined as subjects having both mucosal healing and histologic healing was evaluated at week 8 of UNIFI-I and week 44 of UNIFI-M.
Estonian: Endoskoopiline normaliseerumine määratleti kui Mayo endoskoopiline alamskoor 0 ja seda täheldati juba uuringu UNIFI-I 8.nädalal.
English: VIAL CARTON TEXT (90 mg)
Estonian: TEKST SÜSTLI PAPPKARBIL (90 mg)
English: Choose and prepare the injection site:
Estonian: Valige välja ja valmistage ette süstekoht.
English: STELARA 45 mg solution for injection in pre-filled syringe Each pre-filled syringe contains 45 mg ustekinumab in 0.5 mL.
Estonian: STELARA, 45 mg süstelahus süstlis Üks süstel sisaldab 45 mg ustekinumabi (ustekinumabum) 0,5 ml lahuses.
English: • the pre-filled syringe is not damaged
Estonian: • kas süstel ei ole kahjustatud;
English: • the number of pre-filled syringes and strength is correct o If your dose is 90 mg you will get one 90 mg pre-filled syringe of Stelara.
Estonian: o kui teie annus on 90 mg, võtate ühe 90 mg Stelara süstli.
English: • Inflammation of tissue under the skin (‘cellulitis') is uncommon (may affect up to 1 in 100 people)
Estonian: • Aeg-ajalt nahaaluskoe põletikku (tselluliit) (võib tekkida kuni 1 kasutajal 100-st).
English: Stelara contains sodium
Estonian: Stelara sisaldab naatriumi
English: ACR 50 response, N (%) ACR 70 response, N (%) Number of patients with ≥ 3% BSA PASI 75 response, N (%) PASI 90 response, N (%) Combined PASI 75 and ACR 20 response, N (%)
Estonian: PASI 90 ravivastus, N (%) Kombineeritud PASI 75 ja ACR 20 ravivastus, N (%)
English: PRE-FILLED SYRINGE CARTON TEXT (45 mg)
Estonian: TEKST SÜSTLI PAPPKARBIL (45 mg)
English: STELARA 90 mg solution for injection in pre-filled syringe Each pre-filled syringe contains 90 mg ustekinumab in 1 mL.
Estonian: STELARA, 90 mg süstelahus süstlis Üks süstel sisaldab 90 mg ustekinumabi (ustekinumabum) 1 ml lahuses.
English: Patients receiving ustekinumab at the recommended dose showed significant improvements on the histo endoscopic mucosal healing endpoint at week 8 in the ustekinumab group (18%) as compared to theplacebo group (9%).
Estonian: Histoendoskoopilise limaskesta paranemise kombineeritud tulemusnäitaja määratleti kui patsiendid, kellel esines nii limaskesta paranemine kui ka histoloogiline paranemine, hinnatuna 8. nädalal uuringus UNIFI-I ja 44. nädalal uuringus UNIFI-M. Patsientidel, kellele manustati ustekinumabi soovitatavaid annuseid, esines 8. nädalal märkimisväärne histoendoskoopiline limaskesta tulemusnäitaja paranemine ustekinumabi rühmas (18%) võrreldes platseeborühmaga (9%).
English: Common: Dizziness, headache Uncommon: Facial palsy
Estonian: Sage: pearinglus, peavalu Aeg-ajalt: näo halvatus
English: • Shingles (a type of painful rash with blisters) are uncommon (may affect up to 1 in
Estonian: • Esineb aeg-ajalt vöötohatist (teatud valulik villiline lööve) (võib tekkida kuni 1 kasutajal
English: Ulcerative colitis is an inflammatory disease of the bowel.
Estonian: Haavandiline koliit on põletikuline soolehaigus.
English: Each vial is for single use only and any unused medicinal product should be disposed of in accordance with local requirements.
Estonian: Kasutamata ravimpreparaat tuleb hävitada vastavalt kohalikele nõuetele.
English: STELARA 130 mg concentrate for solution for infusion ustekinumab
Estonian: STELARA, 130 mg infusioonilahuse kontsentraat Ustekinumab (ustekinumabum)
English: Solution for injection in pre-filled syringe 90 mg/1 mL
Estonian: Süstelahus süstlis 90 mg/1 ml 1 süstel
English: Stelara.
Estonian: ustekinumabile.
English: Psoriasis Study 1
Estonian: Psoriaasi uuring 1 Randomiseeritud patsientide arv
English: STELARA 130 mg concentrate for solution for infusion
Estonian: STELARA, 130 mg infusioonilahuse kontsentraat
English: It is supplied as a carton pack containing 1 single-dose, glass 1 mL pre-filled syringe.
Estonian: Lahus on saadaval pakendites, milles on 1 klaasist ühekordse annuse 1 ml süstel.
English: After the starting dose, you will receive the next dose of 90 mg Stelara after 8 weeks, then every 12 weeks thereafter by an injection under the skin (‘subcutaneously').
Estonian: 8 nädalat pärast algannust manustatakse teile nahaaluse süstena (subkutaanselt) järgmine Stelara annus 90 mg ning seejärel jätkatakse annuste manustamist iga 12 nädala järel.
English: * See section 4.4, Systemic and respiratory hypersensitivity reactions.
Estonian: Süsteemsed ja respiratoorsed ülitundlikkusreaktsioonid.
English: Serious skin conditions
Estonian: RAVIMI VÄLJASTAMISTINGIMUSED
English: Each vial contains 90 mg ustekinumab in 1 mL.
Estonian: Üks süstel sisaldab 90 mg ustekinumabi 1 ml lahuses.
English: STELARA 45 mg solution for injection Ustekinumab
Estonian: STELARA, 45 mg süstelahus Ustekinumab (ustekinumabum)
English: Dose
Estonian: PASI
English: Sucrose
Estonian: PedsQL
English: STELARA 45 mg solution for injection in pre-filled syringe Ustekinumab
Estonian: STELARA, 45 mg süstelahus süstlis Ustekinumab (ustekinumabum)
English: See the package leaflet for further information.
Estonian: Lisainformatsiooni vt pakendi infolehelt.
English: STELARA 90 mg solution for injection ustekinumab
Estonian: STELARA, 90 mg süstelahus Ustekinumab (ustekinumabum)
English: The European Commission granted a marketing authorisation valid throughout the European Union for Suboxone on 26 September 2006.
Estonian: Euroopa Komisjon andis Suboxone müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 26. septembril 2006.
English: A risk management plan has been developed to ensure that Suboxone is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Suboxone võimalikult ohutu kasutamine.
English: The tablets must never be swallowed but should be placed under the tongue and allowed to dissolve, which usually takes five to 10 minutes.
Estonian: Tabletti ei tohi neelata, vaid see tuleb asetada keele alla ja lasta sellel suus lahustuda, mis kestab tavaliselt 5-10 minutit.
English: What measures are being taken to ensure the safe and effective use of Suboxone?
Estonian: Mis meetmed võetakse, et tagada Suboxone ohutu ja efektiivne kasutamine?
English: Suboxone buprenorphine / naloxone
Estonian: Suboxone buprenorfiin/naloksoon
English: Other information about Suboxone
Estonian: Muu teave Suboxone kohta
English: The full EPAR for Suboxone can be searched for on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports For more information about treatment with Suboxone, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Euroopa avaliku hindamisaruande täistekst Suboxone kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports Kui vajate Suboxonega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Once the patient has been stabilised, the maintenance dose may be reduced gradually and eventually treatment may be stopped.
Estonian: Kui patsiendi seisund on stabiliseerunud, tohib säilitusannust järkjärgult vähendada ja lõpuks ravi lõpetada.
English: ‘Sublingual' means that the tablet is placed under the tongue where it dissolves.
Estonian: „Keelealune” tähendab, et tablett lahustub keele all.
English: Suboxone is used in adults and children over 15 years of age, who are also receiving medical, social and psychological support.
Estonian: Suboxonet kasutatakse täiskasvanutel ja vähemalt 15-aastastel noorukitel, kes saavad ka meditsiinilist, sotsiaalset ja psühholoogilist abi.
English: The Committee decided that Suboxone's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Komitee otsustas, et Suboxone kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
English: It is available as sublingual tablets containing 2 mg buprenorphine and 0.5 mg naloxone, 8 mg buprenorphine and 2 mg naloxone, or 16 mg buprenorphine and 4 mg naloxone.
Estonian: Seda turustatakse keelealuste tablettidena, mis sisaldavad 2 mg buprenorfiini ja 0,5 mg naloksooni, 8 mg buprenorfiini ja 2 mg naloksooni või 16 mg buprenorfiini ja 4 mg naloksooni.
English: The effectiveness of Suboxone treatment depends on the patient also receiving other medical, social and psychological support.
Estonian: Suboxone-ravi efektiivsus sõltub sellest, kas patsient saab ka meditsiinilist, sotsiaalset ja psühholoogilist abi.
English: Sublingual tablets containing buprenorphine alone have been available in the EU since the mid-1990's for the treatment of opioid addiction.
Estonian: Ainult buprenorfiini sisaldavad keelealuseid opioidisõltuvuse tablette on Euroopa Liidus turustatud alates 1990. aastate keskpaigast.
English: The recommended starting dose is one or two tablets of Suboxone 2 mg/0.5 mg.
Estonian: Soovituslik algannus on üks või kaks Suboxone 2 mg / 0,5 mg tabletti.
English: This document is a summary of the European public assessment report (EPAR) for Suboxone.
Estonian: See on ravimi Suboxone Euroopa avaliku hindamisaruande kokkuvõte.
English: The way Suboxone is used depends on the patient's status: type of addiction, state of withdrawal, and whether the patient is already using another substitution treatment such as methadone before starting Suboxone.
Estonian: Suboxone kasutusviis sõltub patsiendi sõltuvuse tüübist, võõrutusastmest ja sellest, kas patsient kasutas enne ravi alustamist Suboxonega juba muud asendusravimit, näiteks metadooni.
English: The CHMP noted that the combination of an opioid analogue with an opioid antagonist is an established strategy for reducing the potential misuse of the medicine.
Estonian: Inimravimite komitee märkis, et opioidianaloogi kombineerimine opioidiantagonistiga on kindel strateegia võimaliku kuritarvitamise vähendamiseks.
English: It is recommended that the patient's liver be checked before starting treatment with Suboxone and should also be monitored regularly during treatment.
Estonian: Enne Suboxoneravi alustamist on soovitatav kontrollida patsiendi maksa ning seda tuleb regulaarselt jälgida ka ravi ajal.
English: The most common side effects with Suboxone (seen in more than 1 patient in 10) are insomnia (difficulty sleeping), constipation, nausea (feeling sick), sweating, headache and withdrawal syndrome.
Estonian: Suboxone kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on unetus, kõhukinnisus, iiveldus, higistamine, peavalu ja võõrutussündroom.
English: Suboxone is a medicine that contains two active substances, buprenorphine and naloxone.
Estonian: Suboxone on ravim, mis sisaldab kaht toimeainet - buprenorfiini ja naloksooni.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Suboxone, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Suboxone omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: It must also not be used in patients with acute alcohol intoxication (excessive alcohol consumption), delirium tremens (a condition caused by alcohol withdrawal) or together with medicines known as opioid antagonists used for the treatment of alcohol or opioid dependence.
Estonian: Seda ei tohi kasutada ka akuutse alkoholimürgistuse või delirium tremensi korral (alkoholi võõrutusel tekkiv seisund) ega koos opioidiantagonistidega, mida kasutatakse alkoholi- või opioidisõltuvuse raviks.
English: Suboxone contains two active substances: buprenorphine, a partial opioid agonist (it acts like an opioid drug), and naloxone, an opioid antagonists (it counteracts the effects of opioid drugs).
Estonian: Suboxone sisaldab kahte toimeainet: buprenorfiini, mis on opioidi agonist (toimib sarnaselt opioidse narkootikumiga), ja naloksooni, mis on opioidiantagonist (omab opioidsele narkootikumile vastupidist toimet).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Suboxone.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: One main study compared Suboxone with buprenorphine on its own or with placebo (a dummy treatment) in 326 heroin-dependent patients for four weeks, and measured the percentage of patients who had no trace of opioids in their urine at the end of the study.
Estonian: Ühes põhiuuringus võrreldi Suboxonet ainult buprenorfiiniga või platseeboga (näiv ravim) 326 heroiinisõltuvusega patsiendil 4 nädala jooksul ning leiti nende patsientide osakaal, kelle uriinis puudusid uuringu lõpus opioidid.
English: Suboxone must not be used in patients with severe respiratory insufficiency (difficulty breathing) or severe liver problems.
Estonian: Ravimit ei tohi kasutada raske hingamispuudulikkuse või raske maksahaigusega patsiendid.
English: For the full list of all side effects reported with Suboxone, see the package leaflet.
Estonian: Suboxone kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What is Suboxone?
Estonian: Mis on Suboxone?
English: Patients also used a specially designed questionnaire to record their cravings, and the change in the questionnaire score before and at the end of the study was measured.
Estonian: Patsiendid kasutasid narkootikumivajaduse ülesmärkimiseks spetsiaalset küsimustikku, mille põhjal võrreldi enne ja pärast uuringut märgitud punktisummat.
English: Suboxone is used to treat dependence on opioid (narcotic) drugs such as heroin or morphine in drug addicts who have agreed to be treated for their addiction.
Estonian: Suboxonet kasutatakse heroiini ja morfiini (opioidid) sõltuvuse raviks patsientidel, kes on andnud sõltuvuse raviks nõusoleku.
English: Why has Suboxone been approved?
Estonian: Miks Suboxone heaks kiideti?
English: What is the risk associated with Suboxone?
Estonian: Mis riskid Suboxonega kaasnevad?
English: Suboxone was as effective as buprenorphine on its own and more effective than placebo: 17.8% of the patients who received Suboxone had a urine sample that tested negative at the end of the study, compared with 5.8% of the patients receiving placebo.
Estonian: Suboxone oli sama efektiivne kui ainult buprenorfiin ja efektiivsem kui platseebo: Suboxonet saanud patsientidest oli uriinianalüüs uuringu lõpus negatiivne 17,8%-l ja platseeborühmas 5,8%-l. Narkootikumivajaduse punktisumma oli enne ravi 62,4-65,6.
English: Suboxone must be used under the supervision of a doctor who has experience in the management of opioid addiction.
Estonian: Suboxonet tohib kasutada üksnes opioidisõltuvuse ravis kogenud arsti järelevalve all.
English: However, buprenorphine tablets have been misused by drug addicts who dissolve the tablets and inject themselves with the resulting solution.
Estonian: Sõltlased on buprenorfiini tablette siiski väärtarvitanud neid lahustades ja lahust süstides.